Hirohiko Shibayama. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Anemia/etiologyBone Density Conservation Agents/therapeutic useBone Diseases, Metabolic/drug therapyBone Diseases, Metabolic/etiologyBoronic Acids/adverse effectsBoronic Acids/therapeutic useBortezomibDiphosphonates/therapeutic useHumansHypercalcemia/etiologyKidney Diseases/drug therapyKidney Diseases/etiologyLenalidomideMultiple Myeloma/complicationsMultiple Myeloma/drug therapyPeripheral Nervous System Diseases/drug therapyPeripheral Nervous System Diseases/etiologyPyrazines/adverse effectsPyrazines/therapeutic useThalidomide/adverse effectsThalidomide/analogs & derivativesThalidomide/therapeutic use
Substances: See more » Bone Density Conservation AgentsBoronic AcidsDiphosphonatesPyrazinesThalidomideBortezomibLenalidomide
Year: 2014 PMID: 25297765
Source DB: PubMed Journal: Rinsho Ketsueki ISSN: 0485-1439